Autolus Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company focused on programmed T cell therapies, has announced its participation in three major upcoming investor conferences in June 2025:

• William Blair 45th Annual Growth Stock Conference on June 3 in Chicago (investor meetings)
• Jefferies Global Healthcare Conference on June 5 in New York (fireside chat with CEO Dr. Christian Itin)
• Goldman Sachs 46th Annual Global Healthcare Conference on June 11 in Miami (fireside chat with CFO Rob Dolski)

Webcasts of the fireside chats will be available on the company's website and archived for 90 days after the presentations.

News Market Reaction – AUTL

%

1 alert

% News Effect

On the day this news was published, AUTL declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences.

William Blair 45^th Annual Growth Stock Conference
Management to host investor meetings
Date: June 3, 2025
Location: Chicago, IL

Jefferies Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 5, 2025; 3:10pm EDT / 20:10pm BST
Location: New York, NY
Presenter: Chief Executive Officer Dr. Christian Itin

Goldman Sachs 46^th Annual Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 11, 2025; 1:20pm EDT / 18:20 BST
Location: Miami, FL
Presenter: Chief Financial Officer Rob Dolski

A webcast of the fireside chats will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com. 

Contact:

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

Olivia Manser 
+44 7780 471 568 
o.manser@autolus.com 

FAQ

Which investor conferences will Autolus Therapeutics (AUTL) attend in June 2025?

Autolus will attend three conferences: William Blair Growth Stock Conference (June 3), Jefferies Global Healthcare Conference (June 5), and Goldman Sachs Global Healthcare Conference (June 11).

Who will be presenting at Autolus Therapeutics' (AUTL) upcoming investor conferences?

CEO Dr. Christian Itin will present at the Jefferies conference, while CFO Rob Dolski will present at the Goldman Sachs conference.

Where can investors watch Autolus Therapeutics' (AUTL) conference presentations?

Webcasts will be available on the 'Events' page in the 'Investor Relations & Media' section of Autolus' website at autolus.com, with replays available for 90 days.

What type of company is Autolus Therapeutics (AUTL)?

Autolus Therapeutics is an early commercial-stage biopharmaceutical company that develops, manufactures, and delivers next-generation programmed T cell therapies.